Home › Companies › KRYSTAL BIOTECH INC. › 2024-2025
Compiled from SEC Form N-PX filings and KRYSTAL BIOTECH INC.’s Form 8-K, filed 2025-05-19 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore KRYSTAL BIOTECH INC. in the interactive database Compare manager voting policies
These tallies are KRYSTAL BIOTECH INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-19 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Daniel S. Janney | 19,838,511 | -- | -- | 4,134,755 | 3,770,846 | Majority: yes |
| Elect Director: Dino A. Rossi | 23,336,879 | -- | -- | 636,387 | 3,770,846 | Majority: yes |
| Elect Director: E. Rand Sutherland, M.D. | 23,337,104 | -- | -- | 636,162 | 3,770,846 | Majority: yes |
| Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year en | 27,723,997 | 14,761 | 5,354 | -- | -- | Majority: yes |
| Proposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers for the fiscal year ended | 22,543,683 | 1,423,437 | 6,146 | -- | 3,770,846 | Majority: yes |
Source: KRYSTAL BIOTECH INC., Form 8-K, filed with the SEC on 2025-05-19 — read the filing on EDGAR.
Each item below shows how the 308 asset managers that disclosed a KRYSTAL BIOTECH INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Meeting held 2025-05-16.
Combines 11 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
KRYSTAL BIOTECH INC.’s own tally for this item (“Proposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers for t”): 22,543,683 for, 1,423,437 against, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 28,899,000 outstanding shares: 78% for, 5% against (83% of the company cast a for/against vote).
The 303 asset managers below cast 92% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,951,227 | 0 | 0 | 0 | For |
| BlackRock | 2,935,499 | 10,371 | 0 | 0 | For |
| Vanguard | 2,857,810 | 2 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 2,201,928 | 0 | 0 | 0 | For |
| Capital Group | 0 | 1,841,572 | 0 | 0 | Against |
| State Street | 1,724,882 | 31,153 | 0 | 0 | For |
| T. Rowe Price | 1,151,686 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 737,675 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 688,460 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 607,386 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 487,191 | 0 | 0 | 0 | For |
| Charles Schwab | 476,799 | 0 | 0 | 0 | For |
| Dimensional | 446,430 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 302,941 | 0 | 0 | 0 | For |
| Invesco | 298,159 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 288,123 | 0 | 0 | 0 | For |
| Nuveen | 268,158 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 235,396 | 0 | 0 | 0 | For |
| Woodline Partners LP | 218,043 | 0 | 0 | 0 | For |
| TIAA | 190,300 | 0 | 0 | 0 | For |
| Northern Trust | 173,302 | 0 | 0 | 0 | For |
| Victory Capital | 149,496 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 132,571 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 126,507 | 0 | 0 | 0 | For |
| Aberdeen | 114,066 | 0 | 0 | 0 | For |
Showing the 25 largest of 303 asset managers. See all 303 in the interactive database.
Meeting held 2025-05-16.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
KRYSTAL BIOTECH INC.’s own tally for this item (“Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm fo”): 27,723,997 for, 14,761 against, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 28,899,000 outstanding shares: 96% for, 0.1% against (96% of the company cast a for/against vote).
The 103 asset managers below cast 99.9% of the shares they voted on this item FOR (13,376,313 for, 11,054 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,666,746 | 0 | 0 | 0 | For |
| Vanguard | 2,767,241 | 0 | 0 | 0 | For |
| BlackRock | 2,322,314 | 0 | 0 | 0 | For |
| Capital Group | 887,104 | 0 | 0 | 0 | For |
| State Street | 635,913 | 0 | 0 | 0 | For |
| T. Rowe Price | 492,535 | 0 | 0 | 0 | For |
| Dimensional | 392,584 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 302,941 | 0 | 0 | 0 | For |
| Charles Schwab | 226,541 | 0 | 0 | 0 | For |
| TIAA | 190,300 | 0 | 0 | 0 | For |
| Invesco | 123,297 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 97,369 | 0 | 0 | 0 | For |
| Lord Abbett | 86,545 | 0 | 0 | 0 | For |
| Jackson National | 86,420 | 0 | 0 | 0 | For |
| Equitable | 72,606 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 63,927 | 0 | 0 | 0 | For |
| Aberdeen | 57,033 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 53,792 | 0 | 0 | 0 | For |
| Victory Capital | 53,301 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 46,800 | 0 | 0 | 0 | For |
| John Hancock | 45,904 | 0 | 0 | 0 | For |
| Voya | 43,785 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 42,274 | 0 | 0 | 0 | For |
| Lincoln Financial | 39,936 | 0 | 0 | 0 | For |
| Nuveen | 36,953 | 0 | 0 | 0 | For |
Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.
Meeting held 2025-05-16.
Combines 6 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
KRYSTAL BIOTECH INC.’s own tally for this item (“Elect Director: Daniel S. Janney”): 19,838,511 for, 4,134,755 withheld, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 28,899,000 outstanding shares: 69% for, 14% withheld (83% of the company cast a for/withheld vote).
The 101 asset managers below cast 100% of the shares they voted on this item FOR (11,801,640 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,666,746 | 0 | 0 | 0 | For |
| Vanguard | 2,766,174 | 0 | 1,067 | 0 | For |
| BlackRock | 2,322,314 | 0 | 0 | 0 | For |
| Capital Group | 887,104 | 0 | 0 | 0 | For |
| State Street | 617,834 | 0 | 18,079 | 0 | For |
| T. Rowe Price | 361,668 | 0 | 130,867 | 0 | For |
| Dimensional | 0 | 0 | 392,584 | 0 | Abstain |
| Manager Directed Portfolios | 302,941 | 0 | 0 | 0 | For |
| Charles Schwab | 226,541 | 0 | 0 | 0 | For |
| TIAA | 190,300 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 123,297 | 0 | Abstain |
| MUTUAL FUND SERIES TRUST | 95,781 | 0 | 1,588 | 0 | For |
| Lord Abbett | 0 | 0 | 86,545 | 0 | Abstain |
| Jackson National | 0 | 0 | 86,420 | 0 | Abstain |
| Equitable | 43,146 | 0 | 29,460 | 0 | For |
| NEW ECONOMY FUND | 63,927 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 57,033 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 53,792 | 0 | Abstain |
| Victory Capital | 0 | 0 | 53,301 | 0 | Abstain |
| OBERWEIS FUNDS | 0 | 0 | 46,800 | 0 | Abstain |
| John Hancock | 27,802 | 0 | 18,102 | 0 | For |
| Voya | 0 | 0 | 43,785 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 42,274 | 0 | 0 | 0 | For |
| Lincoln Financial | 26,346 | 0 | 13,590 | 0 | For |
| Nuveen | 36,953 | 0 | 0 | 0 | For |
Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.
Meeting held 2025-05-16.
Combines 6 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
KRYSTAL BIOTECH INC.’s own tally for this item (“Elect Director: Dino A. Rossi”): 23,336,879 for, 636,387 withheld, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 28,899,000 outstanding shares: 81% for, 2% withheld (83% of the company cast a for/withheld vote).
The 101 asset managers below cast 100% of the shares they voted on this item FOR (12,921,619 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,666,746 | 0 | 0 | 0 | For |
| Vanguard | 2,767,240 | 0 | 1 | 0 | For |
| BlackRock | 2,322,314 | 0 | 0 | 0 | For |
| Capital Group | 887,104 | 0 | 0 | 0 | For |
| State Street | 635,913 | 0 | 0 | 0 | For |
| T. Rowe Price | 492,535 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 392,584 | 0 | Abstain |
| Manager Directed Portfolios | 302,941 | 0 | 0 | 0 | For |
| Charles Schwab | 226,541 | 0 | 0 | 0 | For |
| TIAA | 190,300 | 0 | 0 | 0 | For |
| Invesco | 123,297 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 97,369 | 0 | 0 | 0 | For |
| Lord Abbett | 86,545 | 0 | 0 | 0 | For |
| Jackson National | 80,305 | 0 | 6,115 | 0 | For |
| Equitable | 43,146 | 0 | 29,460 | 0 | For |
| NEW ECONOMY FUND | 63,927 | 0 | 0 | 0 | For |
| Aberdeen | 57,033 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 53,792 | 0 | 0 | 0 | For |
| Victory Capital | 53,301 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 46,800 | 0 | 0 | 0 | For |
| John Hancock | 36,612 | 0 | 9,292 | 0 | For |
| Voya | 43,785 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 42,274 | 0 | 0 | 0 | For |
| Lincoln Financial | 37,400 | 0 | 2,536 | 0 | For |
| Nuveen | 36,953 | 0 | 0 | 0 | For |
Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.
Meeting held 2025-05-16.
Combines 6 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
KRYSTAL BIOTECH INC.’s own tally for this item (“Elect Director: E. Rand Sutherland, M.D.”): 23,337,104 for, 636,162 withheld, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 28,899,000 outstanding shares: 81% for, 2% withheld (83% of the company cast a for/withheld vote).
The 101 asset managers below cast 100% of the shares they voted on this item FOR (12,939,819 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,666,746 | 0 | 0 | 0 | For |
| Vanguard | 2,767,240 | 0 | 1 | 0 | For |
| BlackRock | 2,322,314 | 0 | 0 | 0 | For |
| Capital Group | 887,104 | 0 | 0 | 0 | For |
| State Street | 635,913 | 0 | 0 | 0 | For |
| T. Rowe Price | 492,535 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 392,584 | 0 | Abstain |
| Manager Directed Portfolios | 302,941 | 0 | 0 | 0 | For |
| Charles Schwab | 226,541 | 0 | 0 | 0 | For |
| TIAA | 190,300 | 0 | 0 | 0 | For |
| Invesco | 123,297 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 97,369 | 0 | 0 | 0 | For |
| Lord Abbett | 86,545 | 0 | 0 | 0 | For |
| Jackson National | 80,305 | 0 | 6,115 | 0 | For |
| Equitable | 43,146 | 0 | 29,460 | 0 | For |
| NEW ECONOMY FUND | 63,927 | 0 | 0 | 0 | For |
| Aberdeen | 57,033 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 53,792 | 0 | 0 | 0 | For |
| Victory Capital | 53,301 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 46,800 | 0 | 0 | 0 | For |
| John Hancock | 36,612 | 0 | 9,292 | 0 | For |
| Voya | 43,785 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 42,274 | 0 | 0 | 0 | For |
| Lincoln Financial | 37,400 | 0 | 2,536 | 0 | For |
| Nuveen | 36,953 | 0 | 0 | 0 | For |
Showing the 25 largest of 101 asset managers. See all 101 in the interactive database.
Meeting held 2024-05-17 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
KRYSTAL BIOTECH INC.’s own tally for this item (“Proposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers for t”): 21,697,311 for, 851,690 against, per its Form 8-K filed 2024-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 28,899,000 outstanding shares: 75% for, 3% against (78% of the company cast a for/against vote).
The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 98 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| COLDSTREAM CAPITAL MANAGEMENT INC | 0 | 98 | 0 | 0 | Against |
| Echo45 Advisors LLC | 0 | 0 | 0 | 0 | -- |
Ranked by the number of KRYSTAL BIOTECH INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 28,899,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 27.51% |
| 2 | BlackRock | 10.19% |
| 3 | Vanguard | 9.89% |
| 4 | Avoro Capital Advisors LLC | 7.62% |
| 5 | Capital Group | 6.37% |
| 6 | State Street | 6.08% |
| 7 | T. Rowe Price | 3.99% |
| 8 | Redmile Group, LLC | 2.55% |
| 9 | Frazier Life Sciences Management, L.P. | 2.38% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.10% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 14.95% | 13F |
| FMR LLC | 14.85% | DEF14A |
| BlackRock | 13.64% | 13F |
| Krish S. Krishnan | 11.72% | 13G |
| Vanguard Group | 9.78% | 13F |
| Avoro Capital Advisors LLC | 8.88% | DEF14A |
| Suma M. Krishnan | 5.88% | DEF14A |
| STATE STREET CORPORATION | 4.43% | 13G |
| Dimensional Fund Advisors | 1.85% | 13F |
| T. Rowe Price | 1.42% | 13F |
Percentages above are of 28,899,000 shares outstanding, as reported by KRYSTAL BIOTECH INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KRYSTAL BIOTECH INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At KRYSTAL BIOTECH INC.'s shareholder meeting held 2025-05-16, in the 2024-2025 proxy season, 308 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 2,143 separate fund positions. On the most widely held item on that ballot — Approval of the compensation of the Company's named executive officers, on a non-binding… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KRYSTAL BIOTECH INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-19.
KRYSTAL BIOTECH INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.